Gossamer Bio Faces Securities Fraud Lawsuit Over Alleged Placebo Risk Concealment
Gossamer Bio (NASDAQ: GOSS) is facing a securities fraud lawsuit, with shares dropping over 80% in a single day following allegations that executives concealed placebo risks. Institutional investors holding GOSS between June 16, 2025, and February 20, 2026, may seek lead plaintiff status in the class action. The window for lead plaintiff applications closes on June 1, 2026.
Tickers: $GOSS
Topics: class action lawsuit ERISA obligations lead plaintiff securities fraud stock price decline